Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMAZA
2024-513956-14-00Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and azacitidine in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Proportion of event-free patients at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
pembrolizumabazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-513956-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513956-14-00.